{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:20:22Z","timestamp":1793622022126,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T00:00:00Z","timestamp":1254268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00280-009-1125-3","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T07:41:16Z","timestamp":1254210076000},"page":"1165-1172","source":"Crossref","is-referenced-by-count":191,"title":["Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data"],"prefix":"10.1007","volume":"65","author":[{"given":"Anne","family":"von Heideman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5ke","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,30]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","volume":"5","author":"BA Chabner","year":"2005","unstructured":"Chabner BA, Roberts TG Jr (2005) Chemotherapy and the war on cancer. Nat Rev Cancer 5:65\u201372","journal-title":"Nat Rev Cancer"},{"key":"1125_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2796.2003.01098.x","volume":"253","author":"P Nygren","year":"2003","unstructured":"Nygren P, Larsson R (2003) Overview of the clinical efficacy of investigational anticancer drugs. J Internal Med 253:46\u201375","journal-title":"J Internal Med"},{"key":"1125_CR3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"G Kroemer","year":"2008","unstructured":"Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer\u2019s achilles heel. Cancer Cell 13:472\u2013482","journal-title":"Cancer Cell"},{"key":"1125_CR4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrc2468","volume":"8","author":"NC Denko","year":"2008","unstructured":"Denko NC (2008) Hypoxia HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705\u2013713","journal-title":"Nat Rev Cancer"},{"key":"1125_CR5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1517\/14728222.11.5.695","volume":"11","author":"JA Khan","year":"2007","unstructured":"Khan JA, Forouhar F, Tao X, Tong L (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Exp Opin Ther Targets 11:695\u2013705","journal-title":"Exp Opin Ther Targets"},{"key":"1125_CR6","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbrc.2008.01.019","volume":"367","author":"UH Olesen","year":"2008","unstructured":"Olesen UH, Knak Christensen M, Bj\u00f6rkling F, J\u00e4\u00e4ttel\u00e4 M, Buhl Jensen P, Sehested M, Jensby Nielsen S (2008) Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 367:799\u2013804","journal-title":"Biochem Biophys Res Commun"},{"key":"1125_CR7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nsmb0706-563","volume":"13","author":"A Mattevi","year":"2006","unstructured":"Mattevi A (2006) A close look at NAD biosynthesis. Nat Struct Mol Biol 13:563\u2013564","journal-title":"Nat Struct Mol Biol"},{"key":"1125_CR8","first-page":"313","volume":"11","author":"A Progrebniak","year":"2006","unstructured":"Progrebniak A, Schemainda I, Azzam K, Pelka-Fischer R, N\u00fcssler V, Hasmann M (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 11:313\u2013321","journal-title":"Eur J Med Res"},{"key":"1125_CR9","first-page":"2269","volume":"22","author":"S Ekelund","year":"2002","unstructured":"Ekelund S, Larsson R, Nygren P (2002) Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human lymphoma cells. Anticancer Res 22:2269\u20132274","journal-title":"Anticancer Res"},{"key":"1125_CR10","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","volume":"113","author":"A Nahimana","year":"2009","unstructured":"Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjornelund J, Dawson KM, Dupuis M, Duchosal MA (2009) The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematological malignancies. Blood 113:3276\u20133286","journal-title":"Blood"},{"key":"1125_CR11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nsmb1105","volume":"13","author":"JA Khan","year":"2006","unstructured":"Khan JA, Tao X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13:582\u2013588","journal-title":"Nat Struct Mol Biol"},{"key":"1125_CR12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00001813-200111000-00005","volume":"12","author":"A Aleskog","year":"2001","unstructured":"Aleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, H\u00f6glund M, Tholander B, Binderup L, Larsson R, Jonsson E (2001) Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 12:821\u2013827","journal-title":"Anticancer Drugs"},{"key":"1125_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0304-3835(00)00661-3","volume":"26","author":"E Jonsson","year":"2001","unstructured":"Jonsson E, Friberg L, Karlsson M, Hassan S, Nygren P, Kristensen J, Tholander B, Binderup L, Larsson R (2001) In vivo activity of CHS 828 on hollow-fiber cultures of primary human tumour cells from patients. Cancer Lett 26:193\u2013200","journal-title":"Cancer Lett"},{"key":"1125_CR14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00001813-200208000-00008","volume":"13","author":"B-M Frost","year":"2002","unstructured":"Frost B-M, L\u00f6nnerholm G, Nygren P, Larsson R, Lindhagen E (2002) In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs 13:735\u2013742","journal-title":"Anticancer Drugs"},{"key":"1125_CR15","unstructured":"Roulston A, Watson M, Bernier C, Chan H, Gratton M-O, Jang A, Koch E, Lavoie M, Paquette D, Mitchell M, Berger A, Belec L, Billot X, Shore G, Beauparlant P (2007) GMX1777: a novel inhibitor of NAD+ biosynthesis via inhibition of nicotinamide phosphoribosyl transferase. Proc AACR-NCI-EORTC conf Mol Targets Cancer Therapeutics San Francisco: A81"},{"key":"1125_CR16","doi-asserted-by":"crossref","unstructured":"Watson M, Roulston A, Chan H, Goulet D, Bedard D, Turcotte E, Shore G, Viallet J, Beauparlant P (2008) Target identification permits rational development of the prodrug GMX1777 for the treatment of melanoma. Eur J Cancer Suppl 6:A470","DOI":"10.1016\/S1359-6349(08)72404-2"},{"key":"1125_CR17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000063874","volume":"48","author":"S Ekelund","year":"2002","unstructured":"Ekelund S, Persson I, Larsson R, Nygren P (2002) Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and tumour cells from patients. Chemotherapy 48:196\u2013204","journal-title":"Chemotherapy"},{"key":"1125_CR18","first-page":"7436","volume":"63","author":"M Hasmann","year":"2003","unstructured":"Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63:7436\u20137442","journal-title":"Cancer Res"},{"key":"1125_CR19","first-page":"2843","volume":"8","author":"P Hovstadius","year":"2002","unstructured":"Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lonnebo A, Ahlgren J (2002) A phase I study of CHS 828 in patients with solid tumour malignancy. Clin Cancer Res 8:2843\u20132850","journal-title":"Clin Cancer Res"},{"key":"1125_CR20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ejca.2004.12.023","volume":"41","author":"A Ravaud","year":"2005","unstructured":"Ravaud A, Cerny T, Terret C, Wanders J, Nguyen Bui B, Hess D, Droz J-P, Fumoleau P, Twelves C (2005) Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG\/EORTC study. Eur J Cancer 41:702\u2013707","journal-title":"Eur J Cancer"},{"key":"1125_CR21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","volume":"26","author":"K Holen","year":"2008","unstructured":"Holen K, Saltz LB, Hollywood E, Burk K, Hanauske A-R (2008) The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26:45\u201351","journal-title":"Invest New Drugs"},{"key":"1125_CR22","doi-asserted-by":"crossref","first-page":"A3581","DOI":"10.1200\/jco.2009.27.15_suppl.3581","volume":"27","author":"MJ Pishvaian","year":"2009","unstructured":"Pishvaian MJ, Marshall JL, Hwang JJ, Malik S, He AR, Deeken JF, Kelso CB, Cotarla I, Berger MS (2009) A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. J Clin Oncol 27:A3581","journal-title":"J Clin Oncol"},{"key":"1125_CR23","first-page":"A418","volume":"6","author":"MJ Pishvaian","year":"2008","unstructured":"Pishvaian MJ, Hwang JH, Malik S, He AR, Deeken JF, Kelso CB, Dorsch-Vogel K, Berger MS, Marshall JL (2008) A phase 1 trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT). Eur J Cancer 6:A418","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1125-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1125-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1125-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T08:35:51Z","timestamp":1633941351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1125-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,30]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1125-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,30]]}}}